Glenmark Pharmaceuticals Inc., USA launches Lacosamide Oral Solution, 10 mg/mL

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Lacosamide Oral Solution, 10 mg/mL. Glenmark's Lacosamide Oral Solution, 10 mg/mL is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat® Oral Solution, 10 mg/mL of UCB, Inc.

According to IQVIATM sales data for the 12 month period ending October 2024, the Vimpat® Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million*.

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are excited to announce the launch of Lacosamide Oral Solution, 10 mg/mL, strengthening our commitment to bring to market quality and affordable alternatives for patients."

Glenmark's current portfolio includes 201 products authorized for distribution in the U.S. marketplace and 51 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to further enhance and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 1551.40 as compared to the previous close of Rs. 1517.20. The total number of shares traded during the day was 13307 in over 1932 trades.

The stock hit an intraday high of Rs. 1562.00 and intraday low of 1501.50. The net turnover during the day was Rs. 20512929.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 LacosamideOralSolution